Promising results for CML
Tuesday, 09 December, 2008
Melbourne’s ChemGenex has released interim data of its Phase II/III trial of a compound for chronic myeloid leukaemia.
The trial involves 44 patients with the T315I mutation who have not responded to Novartis’ Glivec, or imatinib.
ChemGenex’s compound, omacetaxine mepesuccinate, showed good responses in chronic phase patients and was well tolerated, the company said.
The trial results were reported by trial investigator Jorge Cortes of the MD Anderson Cancer Center at a haematology conference in the US.
ChemGenex CEO Dr Greg Collier said the data would probably form part of the clinical section of the company’s new drug application to the US FDA next year.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
